Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Torsten B. Wagner
Observed names:
T. Wagner,
Torsten Wagner,
Wagner, Torsten
Institution:
Merck Healthcare Germany GmbH (Germany)
Observed institutions:
Merck KGaA, Darmstadt (Germany),
Merck Healthcare Germany GmbH (Germany),
Merck Healthcare KGaA, Darmstadt (Germany)
ORCID:
0009-0005-7479-4311
Observed ORCID:
0009-0005-7479-4311
OpenAlex ID:
A5114007394
Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledge
2018
·
Uwe Klaus Zettl
, Michael Hecker
, et al.
·
Expert Review of Clinical Immunology
·
50
Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation
2023
·
Uwe Klaus Zettl
, Paulus Stefan Rommer
, et al.
·
Expert Review of Clinical Immunology
·
18
PDF
Adherence to Subcutaneous IFN β-1a in Multiple Sclerosis: Final Analysis of the Non-Interventional Study READOUTsmart Using the Dosing Log and Readout Function of RebiSmart®
2018
·
Peter Rieckmann
, Matthias Schwab
, et al.
·
Advances in Therapy
·
15
Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart® Injector: Results of the Prospective Cohort Study REBIFLECT
2022
·
Peter Rieckmann
, Tjalf Ziemssen
, et al.
·
Advances in Therapy
·
6
PDF
Is therapy-free remission a realistic goal with cladribine tablets in multiple sclerosis? New insights into the mechanism of action and clinical implications of immune reconstitution with cladribine tablets in MS therapy
2025
·
C. Kleinschnitz
, T. Skripuletz
, et al.
·
Journal of Neurology
·
5
PDF
Evaluation of therapy satisfaction with cladribine tablets in patients with RMS: Final results of the non-interventional study CLEVER
2024
·
Tjalf Ziemssen
, Anita Posevitz-Fejfár
, et al.
·
Multiple Sclerosis and Related Disorders
·
5
Treatment-free remission in MS: long-term disease control with cladribine tablets
2026
·
Heinz Wiendl
, Ralf Gold
, et al.
·
Journal of Neurology
·
4
PDF
REBISTART: Adherence of Patients with Multiple Sclerosis to Treatment with Subcutaneous Interferon Beta in the Context of a Patient Support Program
2024
·
Matthias Schwab
, Andrew Chan
, et al.
·
Neurology and Therapy
·
3
PDF
Patients with Multiple Sclerosis in Year 5 After Initiation of Treatment with Cladribine Tablets: Analysis of Longitudinal Prescription Data from Germany (P8-6.017)
2024
·
Kristina von der Maßen
, David Kormann
, et al.
·
Neurology
·
1
Treatment Continuation With Cladribine Tablets Beyond Year 4: Analysis of Longitudinal Prescription Data From Germany
2026
·
David Kormann
, Mahir Parekh
, et al.
·
Multiple Sclerosis and Related Disorders
Treatment continuation with cladribine tablets beyond year 4 – second interim analysis of the CLIP-5 study
2026
·
Catharina Korsukewitz
, Nils Richter
, et al.
·
Multiple Sclerosis and Related Disorders
MS disease modifying therapy (DMT) sequencing – natalizumab to cladribine tablets – experience in 67 patients (4104)
2020
·
Nora Moehn
, Tatjana Mihalova
, et al.
·
Neurology
Adherence to Subcutaneous IFN-β1a - Final Analysis of the Non-Interventional Study READOUTsmart Using the Dosing Log and Readout Function of RebiSmart (P3.098)
2016
·
Peter Rieckmann
, Matthias Schwab
, et al.
·
Neurology
Monitoring Adherence in Multiple Sclerosis Using the Electronic Self-Injection Device RebiSmart™: Interim Results of a Noninterventional Study in Patients in Germany (READOUTsmart) (P01.166)
2013
·
Peter Rieckmann
, Matthias Schwab
, et al.
·
Neurology
Show more works
View as search
Works count:
15
Citation count:
107
H-index:
5
I10-index:
3
Year
Topic
Type